Detalles de la búsqueda
1.
Re-Cellularization via Electroporation Therapy of the duodenum combined with GPL-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes; 12 months results of a first-in-human study.
Gastrointest Endosc
; 2024 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38692517
2.
Insulin sensitivity and beta cell function after Duodenal Mucosal Resurfacing (DMR): An Open-Label, Mechanistic, Pilot Study.
Gastrointest Endosc
; 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38280531
3.
Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes.
Am J Physiol Endocrinol Metab
; 322(2): E132-E140, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34957857
4.
Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study.
Gastrointest Endosc
; 94(1): 111-120.e3, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33359437
5.
Alternative treatments for type 2 diabetes and associated metabolic diseases: medical therapy or endoscopic duodenal mucosal remodelling?
Gut
; 70(11): 2196-2204, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34497147
6.
Intervention not always necessary in post-appendectomy abscesses in children; clinical experience in a tertiary surgical centre and an overview of the literature.
Eur J Pediatr
; 175(9): 1185-1191, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27511046
7.
A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study.
Front Clin Diabetes Healthc
; 3: 856661, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36992788
Resultados
1 -
7
de 7
1
Próxima >
>>